EP
RAPP

Essential Partners’s Rapport Therapeutics RAPP Stock Holding History

Essential Partners’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.67K Hold
40
– – ﹤0.01% 2048
2026
Q1 		$1.25K Hold
40
– – ﹤0.01% 2172
2025
Q4 		$1.21K Hold
40
– – ﹤0.01% 1970
2025
Q3 		$1.19K Buy
40
+9
+29% +$161 ﹤0.01% 1967
2025
Q2 		$352 Buy
+31
New +$329 ﹤0.01% 1796

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Essential Partners's RAPP Position: Q2 2026 in Review

Essential Partners held its Rapport Therapeutics (RAPP) position steady in Q2 2026 at 40 shares worth $1.67K. The position accounts for ﹤0.01% of the portfolio, ranked #2048.

Essential Partners first reported a position in RAPP in Q2 2025 and has held it in 5 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Essential Partners held 40 shares of Rapport Therapeutics worth $1.67K as of Q2 2026.
  • Essential Partners left its Rapport Therapeutics share count unchanged in Q2 2026.
  • Rapport Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2048 holding.
  • Essential Partners first reported a position in Rapport Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.